15 Analysts Have This to Say About Biomarin Pharmaceutical
Portfolio Pulse from Benzinga Insights
15 analysts have provided ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) in the last quarter. The average price target is $118.2, compared to the current price of $85.165, implying an upside. This average represents a 9.08% decrease from the previous average price target of $130.00.
October 16, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biomarin Pharmaceutical (NASDAQ:BMRN) has received various ratings from 15 analysts, with an average price target of $118.2, indicating a potential upside.
The average price target given by the analysts is higher than the current price of the stock, indicating a potential upside. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100